ABL Diagnostics (XPAR:ABLD) Moat Score: 0/10 (As of Jul. 06, 2026)


XPAR:ABLD ABL Diagnostics XPAR:ABLD
51 GF Score
Price €2.66
GF Value €7.71
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is ABL Diagnostics Moat Score?

ABL Diagnostics has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

ABL Diagnostics has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes ABL Diagnostics might have No Moat - No discernible moat.

ABL Diagnostics  (XPAR:ABLD) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

ABL Diagnostics Moat Score Related Terms

XPAR:ABLD
51GF Score
ABL Diagnostics XPAR:ABLD
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is ABL Diagnostics (XPAR:ABLD) Overvalued in 2026?

Based on GuruFocus' analysis, ABL Diagnostics stock appears to be undervalued. The current stock price of €2.66 is trading 65.5% below its estimated GF Value™ of €7.71. GuruFocus considers ABL Diagnostics to be Significantly Undervalued.

Key valuation signals for XPAR:ABLD:

  • Moat Score: 0
  • GF Value™: €7.71 vs. price of €2.66 (65.5% below fair value)
  • GF Score™: 51/100 with 4 warning signs

No single metric tells the full story. See the XPAR:ABLD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ABL Diagnostics Business Description

Other Exchanges 9BK0:Germany
Address 72c, rue de, WOIPPY, Thionville, FRA, 57140
ABL Diagnostics is a diagnostic and medical software company. The group has focused on the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. It also develops, manufactures, and markets kits for clinical specimen collection.
51GF Score

Get the complete analysis for XPAR:ABLD

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.66
Price
€7.71
GF Value